Asphalion expert Diego Hernández Pedraza attended the meeting. Asphalion is providing regulatory guidance to support understanding of the environmental exposure and ecotoxicity during pharmaceuticals development to ensure the solutions are commercially deployable in the future, ensuring this will be achieved by creating a new concept paper on compliance-by-design key-drivers and roadmap of the possible regulatory pathways or relevant regulatory frameworks and strategies. The approach will be carried out according to applicable regulatory guidelines and technical standards. Due to Asphalion’s expertise in the regulatory field, Asphalion will also engage with policy makers, regulators and standards bodies to ensure a regulatory framework that enables green innovation.
Currently the stakeholders taking part in the ETERNAL initiative are at the forefront of pioneering new manufacturing technologies and identifying critical drivers for integration into pharmaceutical industry processes. The amalgamation of novel synergies and diverse perspectives from academic research institutions, pharmaceutical corporations, independent entities, and regulatory bodies, is poised to bolster the control and implementation of these innovative technologies. This collective effort is targeted at reducing the carbon footprint across the entire pharmaceutical supply chain, from inception to the eventual disposal of unused medicines. This endeavor represents a significant stride towards environmentally conscious practices within the pharmaceutical industry.
For further information about the project or for assistance, reach out to us! Send an email at: [email protected]
